Inidascamine (RL-007)

Unknown / undisclosed

Phase 2Undisclosed / early pipeline
Phase 2topline reported

Evidence outlook

Cognitive Impairment Associated with Schizophrenia: topline reported 2025-07-25

The sponsor reported topline results on 2025-07-25 (Phase 2b CIAS topline: inidascamine missed the primary endpoint). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Cognitive Impairment Associated with Schizophrenia

Competitive landscape

This drug's own stage for Cognitive Impairment Associated with Schizophrenia: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Inidascamine (RL-007): this drugPhase 2——not yet gradedNo reviewed efficacy summary in this indication
ALTO-101
Phase 2(overall)
Small moleculePDE4not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

25 July 2025Topline resultPhase 2b CIAS topline: inidascamine missed the primary endpoint
Recognify Life Sciences · Source ↗